Ketamine response in treatment-resistant depression depends on multiple interconnected factors including depression severity, anxiety levels, sleep patterns, inflammation markers, genetic variations, and brain activity patterns, according to a 2026 systematic review of 150 studies. Research shows that glutamate system function, circadian rhythms, and inflammation interact to determine who benefits most from ketamine treatment. However, these predictors remain exploratory and require prospective validation before doctors can use them routinely to personalize treatment decisions.
Researchers reviewed 150 studies to understand why ketamine works quickly for some people with severe depression but not others. According to Gram Research analysis, the answer isn’t simple: your genes, brain chemistry, sleep patterns, inflammation levels, and how quickly you improve in the first few days all play a role. Scientists found that ketamine’s effectiveness depends on multiple factors working together, like a combination lock where several numbers need to be right. This review suggests doctors might one day use blood tests, brain scans, and questionnaires to predict who will benefit most before starting treatment, making depression care more personalized.
Key Statistics
A 2026 systematic review analyzing 150 studies found that ketamine response in treatment-resistant depression is predicted by multiple factors including baseline depression severity, comorbid anxiety, sleep phenotypes, inflammatory biomarkers like monocyte count, genetic variants, and early symptomatic improvement within the first few days of treatment.
According to research reviewed by Gram, metabolic factors including BMI and vitamin B12 levels, along with neurophysiological signatures measured by EEG and fMRI brain connectivity, contribute to predicting individual ketamine response in adults with major depressive and bipolar disorders.
A comprehensive analysis of 150 ketamine studies identified that glutamatergic, circadian, and inflammatory mechanisms interact to shape why some people respond to intravenous ketamine while others do not, though most proposed predictors remain exploratory and require prospective validation.
The Quick Take
- What they studied: What factors predict whether intravenous ketamine will effectively treat severe depression that hasn’t responded to other medications?
- Who participated: Analysis of 150 published research studies involving adults with major depression or bipolar disorder who received intravenous ketamine treatment.
- Key finding: Ketamine response depends on multiple interconnected factors including baseline depression severity, anxiety levels, sleep problems, brain inflammation markers, genetic variations, brain activity patterns, and how quickly symptoms improve in the first few days of treatment.
- What it means for you: In the future, doctors might use blood tests, brain measurements, and questionnaires to predict who will benefit from ketamine before starting treatment. However, these predictors are still being studied and aren’t yet ready for routine clinical use.
The Research Details
This was a systematic review, meaning researchers searched four major medical databases (Scopus, PubMed, EMBASE, and MEDLINE) for all published studies about ketamine and treatment-resistant depression from the past 5 years. They followed strict guidelines called PRISMA to ensure they found and evaluated studies fairly. The researchers then read through 150 studies that met their criteria and looked for patterns in what predicted whether ketamine would work.
Instead of doing their own experiment, the researchers were like detectives gathering clues from other scientists’ work. They organized information about different types of predictors: clinical signs (like how severe your depression is), blood markers (like inflammation levels), brain scans and electrical activity, genetic information, and how quickly people improved after their first ketamine dose.
This approach is valuable because it brings together knowledge from many different studies to see the bigger picture. However, because different studies used different methods and measured different things, combining the results was challenging.
Understanding what predicts ketamine response matters because ketamine works very quickly (sometimes within hours or days) compared to traditional antidepressants, but it doesn’t work for everyone. If doctors could predict in advance who will benefit, they could offer ketamine to the right patients and explore other options for those unlikely to respond. This could save time, money, and suffering for people with severe depression.
This review synthesized information from 150 studies, which is a large amount of evidence. However, the studies used different methods and measured different things, making it hard to draw firm conclusions. The researchers were honest about this limitation. Most of the predictors they identified are still exploratory and haven’t been tested in large prospective studies where researchers follow patients forward in time. The review is recent (2026) and covers the latest 5 years of research, which is good for currency.
What the Results Show
The review identified multiple categories of factors that predict ketamine response. Clinical factors include how severe your depression is at the start, whether you have anxiety alongside depression, whether you have atypical depression (with increased appetite and sleep), and sleep problems. These are things doctors can assess through conversation and questionnaires.
Biomarkers, which are measurable substances in your blood or body, also predict response. These include monocyte count (a type of white blood cell related to inflammation), BDNF (a protein that helps brain cells grow and connect), vitamin B12 levels, and BMI (body mass index). Inflammation appears to be a key mechanism: people with higher inflammation may respond differently to ketamine.
Brain-based predictors include genetic variations that affect how your brain uses glutamate (a key brain chemical), EEG patterns (electrical activity of the brain), TMS responses (how your brain reacts to magnetic stimulation), and fMRI connectivity (how different brain regions communicate). Finally, how quickly you improve in the first few days after starting ketamine strongly predicts whether you’ll have a good long-term response.
The researchers found that these factors don’t work in isolation. Instead, they interact through three main biological pathways: the glutamate system (the brain’s main excitatory chemical), circadian rhythms (your body’s internal clock), and inflammation. People’s individual differences in these systems explain why ketamine works better for some than others.
The review highlighted that metabolic factors like vitamin B12 deficiency and elevated BMI may influence ketamine response, though these need more study. Cognitive performance also appeared in some studies as a predictor, suggesting that how well your brain functions in thinking and memory tasks might relate to ketamine response. The research also emphasized that depression phenotypes, or distinct depression subtypes, matter: someone with atypical depression (sleeping more, eating more) may respond differently than someone with typical depression.
This review builds on earlier research by attempting the first comprehensive integration of multiple predictor categories. Previous studies often looked at one type of predictor (like genetics or inflammation) in isolation. This review shows that ketamine response is truly multifactorial, meaning many systems work together. This aligns with modern understanding of depression as a complex condition involving brain chemistry, genetics, inflammation, and circadian biology rather than a single cause.
The main limitation is methodological heterogeneity, meaning the 150 studies used different methods, measured different things, and studied different populations. This makes it hard to combine results statistically. Second, most studies were small and short-term, so long-term outcome data is scarce. Third, most proposed predictors remain exploratory and haven’t been validated in large prospective studies where researchers follow patients forward in time. The researchers were clear that these predictors are not yet ready for routine clinical use. Finally, the review couldn’t determine which predictors are most important or how to weight them in clinical decision-making.
The Bottom Line
Based on current evidence, intravenous ketamine remains an established, rapid-acting treatment for severe depression that hasn’t responded to other medications. However, using specific predictors to personalize treatment is not yet recommended for routine clinical practice. Confidence level: High for ketamine’s general effectiveness; Low to Moderate for using predictors to select patients. Doctors should continue offering ketamine to appropriate candidates while research continues on prediction methods.
This research matters most for people with treatment-resistant depression (depression that hasn’t improved after trying multiple medications), psychiatrists and mental health professionals, researchers studying depression, and pharmaceutical companies developing new treatments. It’s less immediately relevant for people with mild to moderate depression responding well to standard treatments. People considering ketamine should discuss with their doctor whether they’re good candidates based on current clinical criteria, not yet-unvalidated predictors.
Ketamine’s effects can appear within hours to days, which is much faster than traditional antidepressants (which take 2 to 4 weeks). However, the research on using predictors to personalize treatment is still in early stages. It will likely take 3 to 5 more years of research before doctors can reliably use these predictors in clinical practice.
Frequently Asked Questions
How quickly does intravenous ketamine work for depression?
Ketamine can produce symptom improvement within hours to days, much faster than traditional antidepressants which typically take 2 to 4 weeks. However, not everyone responds, and response depends on multiple factors including depression severity, anxiety levels, sleep patterns, and genetic variations.
Can doctors predict who will respond to ketamine before starting treatment?
Researchers have identified multiple potential predictors including blood inflammation markers, genetic factors, brain activity patterns, and vitamin B12 levels. However, these predictors are still exploratory and not yet validated for routine clinical use. Doctors currently select ketamine candidates based on established clinical criteria rather than these emerging predictors.
What role does inflammation play in ketamine response?
A 2026 review of 150 studies found that inflammatory markers like monocyte count appear to predict ketamine response. Inflammation interacts with glutamate system function and circadian rhythms to influence treatment outcomes, suggesting that people with different inflammation levels may respond differently to ketamine.
Are genetic tests available to predict ketamine response?
Genetic variations affecting glutamate system function show promise as predictors in research studies, but genetic testing for ketamine response is not yet available or recommended for clinical use. These findings remain exploratory and require larger prospective studies before implementation.
What should I track if I’m considering ketamine treatment?
Track daily mood ratings, sleep hours and quality, anxiety levels, energy, and appetite. Note the timing of ketamine infusions and any changes in these factors. Early improvement within the first few days is a strong predictor of long-term response, so detailed tracking helps your doctor assess your individual response pattern.
Want to Apply This Research?
- Track daily mood ratings (0-10 scale), sleep hours and quality, anxiety levels, and energy levels starting before ketamine treatment and continuing for at least 2 weeks. Note the exact day and time of ketamine infusions. This creates a personal baseline and response pattern that can be shared with your treatment team.
- Work with your healthcare provider to optimize sleep schedule, maintain consistent meal timing, track vitamin B12 intake through diet or supplements if deficient, and monitor inflammation-related symptoms like joint pain or fatigue. Use the app to log these factors alongside mood to identify personal patterns.
- Create a long-term dashboard showing mood trajectory, sleep patterns, and symptom clusters over months. Set weekly check-ins to rate depression severity, anxiety, and atypical symptoms (appetite, sleep duration). Share monthly summaries with your psychiatrist to refine treatment and identify which factors most influence your personal response.
This article summarizes research on ketamine as a treatment for severe depression. Intravenous ketamine is a medical treatment that should only be administered by qualified healthcare providers in appropriate clinical settings. If you are considering ketamine treatment, discuss with a psychiatrist or mental health professional whether it is appropriate for your specific situation. The predictors discussed in this review are still being researched and are not yet ready for routine clinical use in selecting patients for ketamine therapy. This article is for educational purposes and should not replace professional medical advice, diagnosis, or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.